Structure-based β-secretase (BACE1) inhibitors
Tímea Polgár, György M Keseru1
1Budapest University of Technology and Economics, Hungary. timea.polgar@gmail.com.
Current Pharmaceutical Design
|August 17, 2013
Summary
Alzheimer's disease involves cognitive decline and lacks effective treatments. This review focuses on structure-based developments targeting Beta-site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1), a key enzyme in disease progression.
Area of Science:
- Neuroscience and Molecular Biology
- Biochemistry and Drug Discovery
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, with current treatments offering limited efficacy for both cognitive and non-cognitive symptoms.
- Understanding the molecular mechanisms underlying AD is crucial for developing effective therapeutic strategies.
- Aspartic proteases, a small protease class, have emerged as significant targets in AD research.
Purpose of the Study:
- To summarize key structure-based advancements in the research of Beta-site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1).
- To highlight BACE1 as a prominent target for Alzheimer's disease therapeutics.
- To provide insights into the molecular mechanisms relevant to AD development.
Main Methods:
- Review and synthesis of existing literature on structure-based drug design targeting BACE1.
- Analysis of molecular mechanisms involving aspartic proteases in the context of Alzheimer's disease.
- Focus on structure-activity relationships and computational modeling of BACE1 inhibitors.
Main Results:
- Significant progress has been made in structure-based approaches to inhibit BACE1 activity.
- Detailed structural information of BACE1 has facilitated the design of potent and selective inhibitors.
- These developments offer potential for novel therapeutic interventions against Alzheimer's disease.
Conclusions:
- BACE1 remains a highly promising therapeutic target for Alzheimer's disease, supported by extensive structure-based research.
- Continued investigation into BACE1 structure and function is vital for advancing drug discovery efforts.
- Structure-based strategies are instrumental in developing treatments for the cognitive and non-cognitive symptoms of Alzheimer's disease.
More Related Videos
11:57Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
Published on: June 24, 2025
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:23Inhibitors of Gram-positive Cell Wall Synthesis
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
01:24Caspases
Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...